Capital Research Global Investors boosted its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,183,330 shares of the biopharmaceutical company’s stock after purchasing an additional 71,811 shares during the quarter. Capital Research Global Investors owned about 12.21% of Ultragenyx Pharmaceutical worth $321,937,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Sei Investments Co. acquired a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at $125,000. Pacer Advisors Inc. grew its stake in Ultragenyx Pharmaceutical by 22.6% in the 1st quarter. Pacer Advisors Inc. now owns 3,037 shares of the biopharmaceutical company’s stock valued at $206,000 after buying an additional 560 shares during the last quarter. Strs Ohio grew its stake in Ultragenyx Pharmaceutical by 10.7% in the 1st quarter. Strs Ohio now owns 3,100 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 300 shares during the last quarter. Tocqueville Asset Management L.P. raised its holdings in Ultragenyx Pharmaceutical by 8.0% in the 2nd quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 250 shares during the period. Finally, Ameritas Investment Partners Inc. raised its holdings in Ultragenyx Pharmaceutical by 3.7% in the 1st quarter. Ameritas Investment Partners Inc. now owns 3,226 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 115 shares during the period. 96.07% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/04/ultragenyx-pharmaceutical-inc-rare-shares-bought-by-capital-research-global-investors.html.

In related news, CEO Emil D. Kakkis purchased 7,500 shares of the firm’s stock in a transaction dated Monday, August 28th. The shares were purchased at an average price of $52.52 per share, with a total value of $393,900.00. Following the acquisition, the chief executive officer now directly owns 430,569 shares of the company’s stock, valued at $22,613,483.88. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 9.20% of the company’s stock.

Several brokerages have issued reports on RARE. BidaskClub upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, June 20th. ValuEngine upgraded Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, June 22nd. Cowen and Company reaffirmed an “outperform” rating on shares of Ultragenyx Pharmaceutical in a report on Thursday, June 29th. Stifel Nicolaus reiterated a “buy” rating and set a $111.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 30th. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $71.65.

Ultragenyx Pharmaceutical Inc. (RARE) traded down 0.04% during trading on Wednesday, reaching $56.74. 38,998 shares of the company were exchanged. The company’s market capitalization is $2.41 billion. Ultragenyx Pharmaceutical Inc. has a one year low of $49.56 and a one year high of $91.35. The firm’s 50-day moving average is $54.05 and its 200 day moving average is $60.62.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.72) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.73) by $0.01. During the same period in the previous year, the business posted ($1.46) EPS. On average, analysts anticipate that Ultragenyx Pharmaceutical Inc. will post ($7.14) EPS for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.